Literature DB >> 18036891

Completely resected non-small cell lung cancer: reconsidering prognostic value and significance of N2 metastases.

Marc Riquet1, Patrick Bagan, Françoise Le Pimpec Barthes, Eugeniu Banu, Florian Scotte, Christophe Foucault, Antoine Dujon, Claire Danel.   

Abstract

BACKGROUND: Non-small cell lung cancer (NSCLC) mediastinal (N2) metastases are indicators of poor prognosis. Survival rates decrease with increasing number of N2 stations and involved lymph nodes as well as lymph node size and capsular invasion. Our purpose was to elucidate the impact lymph node-related variables on the outcome after surgical resection.
METHODS: We reviewed data of 2344 NSCLC patients who underwent curative resections with mediastinal lymphadenectomy, and 586 (25%) had N2 metastases. We studied the overall survival of N2 patients according to some important covariates.
RESULTS: Metastases involved single N2 stations in 386 patients (66%) and two or more in 200 (34%). Survival was not related with histology or pathologic tumor (pT), but was better when only one N2 station was involved (5-year overall survival 28.5% [median, 24 months] versus 17.2% [median, 14 months] respectively; p = 0.0002. For single N2 stations, capsular rupture, number, and size of lymph nodes were not significant prognostic factors. When the size of lymph node was analyzed (micrometastases, 53; nonbulky, 207; or bulky metastases, 126), overall survival differences between nonbulky and bulky N2 were significant: 5-year overall survival was 34% (median, 28 months) versus 23% (median, 23 months), respectively (p = 0.026). Presence of micrometastases was associated with a poor prognosis: 5-year overall survival of 21.4% (median, 23 months).
CONCLUSIONS: Prognosis was better for patients with single N2 stations when metastatic lymph nodes were not enlarged. However, the presence of lymph nodes micrometastases does not seems associated with a better outcome.

Entities:  

Mesh:

Year:  2007        PMID: 18036891     DOI: 10.1016/j.athoracsur.2007.07.015

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  19 in total

1.  Analysis of prognostic factors for surgery after neo-adjuvant therapy for stage III non-small cell lung cancer.

Authors:  Xuefeng Zhou; Jianjun Wang; Jiashun Wang; Yongcheng Pan; Jingsong Li; Wendong Wang; Feng Zhao
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2008-12-24

2.  Prognostic Factors for Surgically Resected N2 Non-small Cell Lung Cancer.

Authors:  Keishi Kawasaki; Yasunori Sato; Yoshio Suzuki; Haruhisa Saito; Yukihiro Nomura; Yukihiro Yoshida
Journal:  Ann Thorac Cardiovasc Surg       Date:  2015-01-26       Impact factor: 1.520

3.  Occult pN2 disease in lung cancer patients: a wide range of diseases endangering the long term prognosis.

Authors:  Marc Riquet; Ciprian Pricopi; Giuseppe Mangiameli; Alex Arame; Alain Badia; Françoise Le Pimpec Barthes
Journal:  J Thorac Dis       Date:  2017-08       Impact factor: 2.895

4.  Topography of the sentinel node according to the affected lobe in lung cancer.

Authors:  J M Galbis-Caravajal; A Lafuente-Sanchis; M Estors-Guerrero; N Martinez-Hernández; C Fuster-Diana; A Cremades; Á Zúñiga
Journal:  Clin Transl Oncol       Date:  2017-01-27       Impact factor: 3.405

5.  Id-1, Id-2, and Id-3 co-expression correlates with prognosis in stage I and II lung adenocarcinoma patients treated with surgery and adjuvant chemotherapy.

Authors:  Leila Antonângelo; Taila Tuma; Alexandre Fabro; Milena Acencio; Ricardo Terra; Edwin Parra; Francisco Vargas; Teresa Takagaki; Vera Capelozzi
Journal:  Exp Biol Med (Maywood)       Date:  2016-02-10

6.  Prognostic factors in stage III non-small cell lung cancer: a review of conventional, metabolic and new biological variables.

Authors:  Thierry Berghmans; Marianne Paesmans; Jean-Paul Sculier
Journal:  Ther Adv Med Oncol       Date:  2011-05       Impact factor: 8.168

Review 7.  Current status of induction treatment for N2-Stage III non-small cell lung cancer.

Authors:  Masafumi Yamaguchi; Kenji Sugio
Journal:  Gen Thorac Cardiovasc Surg       Date:  2014-07-18

Review 8.  The Role of Surgery in Management of Locally Advanced Non-Small Cell Lung Cancer.

Authors:  Darren S Bryan; Jessica S Donington
Journal:  Curr Treat Options Oncol       Date:  2019-03-14

Review 9.  Controversies regarding T status and N status for non-small cell lung cancer.

Authors:  Yanli Mo; Jiayin Peng; Wenmei Su; Xinggui Chen; Aibing Wu; Jinmei Li; Zhixiong Yang
Journal:  Int J Clin Exp Med       Date:  2015-07-15

10.  Sunlight may increase the FDG uptake value in primary tumors of patients with non-small cell lung cancer.

Authors:  Hasan Mutlu; Abdullah Büyükçelik; Eser Kaya; Mustafa Kibar; Ertuğrul Seyrek; Sinan Yavuz; Züleyha Calikuşu
Journal:  Oncol Lett       Date:  2013-01-07       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.